In vitro activity of ceftaroline against clinical isolates of Streptococcus pneumoniae recovered in 43 U.S. medical centers during 2010-2011

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 6, 2012, Pages 3406-3408

  Doern, Gary V ^a   Diekema, Daniel J ^a   Heilmann, Kristopher P ^a   Dohrn, Cassie L ^a   Riahi, Fathollah ^a   Richter, Sandra S ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAROLINE; CEFTRIAXONE; PENICILLIN G;

ADOLESCENT; ADULT; AGED; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; CHILD; CONTROLLED STUDY; FEMALE; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PENICILLIN RESISTANCE; PNEUMOCOCCAL INFECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; STREPTOCOCCUS PNEUMONIAE;

CEFTRIAXONE; CEPHALOSPORINS; MICROBIAL SENSITIVITY TESTS; PENICILLINS; STREPTOCOCCUS PNEUMONIAE;

EID: 84861161966     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00582-12     Document Type: Article

References (21)

1. Beall B, et al. 2006. Pre- and postvaccination clonal compositions of invasive pneumococcal serotypes for clinical isolates collected in the United States in 1999, 2001, and 2002. J. Clin. Microbiol. 44:999-1017.
2. Clinical and Laboratory Standards Institute. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 8th ed. CLSI document M7-A8. Clinical and Laboratory Standards Institute, Wayne, PA.
3. Clinical and Laboratory Standards Institute. 2009. Performance standards for antimicrobial susceptibility testing; 19th informational supplement. CLSI document M100-S19. Clinical and Laboratory Standards Institute, Wayne, PA.
4. Dagan R. 2009. Impact of pneumococcal conjugate vaccine on infections caused by antibiotic-resistant Streptococcus pneumoniae. Clin. Microbiol. Infect. 15:16-20.
5. Doern GV, et al. 2005. Antimicrobial resistance with Streptococcus pneumoniae in the United States-as fluoroquinolone resistance emerges, have we turned the corner on resistance to other antimicrobial classes? Clin. Infect. Dis. 41:139-148. (Pubitemid 40962493)
6. Farrell DJ, Klugman KP, Pichichero M. 2007. Increased antimicrobial resistance among nonvaccine serotypes of Streptococcus pneumoniae in the pediatric population after introduction of the 7-valent pneumococcal vaccine in the United States. Pediatr. Infect. Dis. J. 26:123-128. (Pubitemid 46183361)
7. Green MC, et al. 2011. Increase in prevalence of Streptococcus pneumoniae serotype 6C at eight children's hospitals in the United States from 1993 to 2009. J. Clin. Microbiol. 49:2097-2101.
8. Hsu KK, Shea KM, Stevenson AE, Pelton SI. 2010. Changing serotypes causing childhood invasive pneumococcal disease: Massachusetts, 2001-2007. Pediatr. Infect. Dis. 29:289-293.
9. Issacman DJ, McIntosh ED, Reinert RR. 2010. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int. J. Infect. Dis. 14:197-209.
10. Jacobs MR, et al. 2010. Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States. Antimicrob. Agents Chemother. 54:2716-2719.
11. Jones RN, Farrell DJ, Mendes RE, Sader HS. 2011. Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: results from an international surveillance study. J. Antimicrob. Chemother. 66:69-80.
12. Jones RN, Jacobs MR, Sader HS. 2010. Evolving trends in Streptococcus pneumoniae resistance: implications for therapy of community-acquired bacterial pneumonia. Int. J. Antimicrob. Agents 36:197-204.
13. Karnezis TT, Smith A, Whittier S, Haddad J, Saiman L. 2009. Antimicrobial resistance among isolates causing invasive pneumococcal disease before and after licensure of heptavalent conjugate pneumococcal vaccine. PLoS One 4:e5965.
14. Kosowska-Shick K, McGhee PL, Appelbomb PC. 2010. Affinity of ceftaroline and other β-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob. Agents Chemother. 54:1670-1677.
15. Linares J, Ardanuy C, Pallares R, Fenoll A. 2010. Changes in antimicrobial resistance, serotypes and genotypes in Streptococcus pneumoniae over a 30-year period. Clin. Microbiol. Infect. 16:402-410.
16. McGee L, et al. 2009. In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococus pneumoniae. Antimicrob. Agents Chemother. 53:552-556.
17. Millar EV, et al. 2010. Pre- and post-conjugate vaccine epidemiology of pneumococcal serotype 6C invasive disease and carriage within Navajo and White Mountain Apache communities. Clin. Infect. Dis. 51:1258-1265.
18. Morrissey I, Ge Y, Janes R. 2009. Activity of the new cephalosporin ceftaroline against bacteriemia isolates from patients with community-acquired pneumonia. Int. J. Antimicrob. Agents 33:515-519.
19. Richter SS, et al. 2009. Changing epidemiology of antimicrobial resistant Streptococcus pneumoniae in the United States, 2004-05. Clin. Infect. Dis. 48:23-33.
20. Sahm DF, Brown NP, Draghi DC, Evangelista AT, Yee YC, Thornsberry C. 2008. Tracking resistance among bacterial respiratory tract pathogens: summary of findings of the TRUST Surveillance Initiative, 2001-2005. Postgrad. Med. 120(3 Suppl 1):8-15.
21. Techasaensiri C, et al. 2010. Epidemiology and evolution of invasive pneumococcal disease caused by multidrug resistant serotypes of 19A in the 8 years after implementation of pneumococcal conjugate vaccine immunization in Dallas, Texas. Pediatr. Infect. Dis. J. 29:294-300.